Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Aug 14, 2019

SELL
$1.8 - $3.3 $299,644 - $549,347
-166,469 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$2.41 - $5.91 $244,540 - $599,681
101,469 Added 156.11%
166,469 $451,000
Q4 2018

Feb 12, 2019

BUY
$3.94 - $9.7 $256,100 - $630,500
65,000 New
65,000 $312,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Quantitative Investment Management, LLC Portfolio

Follow Quantitative Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantitative Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quantitative Investment Management, LLC with notifications on news.